Oral Tranexamic Acid for Shoulder Replacement Surgery

Overseen By Walter Smith

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: University of Alabama at Birmingham

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this clinical trial is to evaluate the short-term clinical outcomes of patients undergoing total shoulder arthroplasty who receive an extended postoperative course of oral tranexamic acid

Research Team

Walter Smith

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

This trial is for patients who are scheduled to undergo total shoulder arthroplasty, which is a type of shoulder replacement surgery. Specific eligibility criteria have not been provided.

Inclusion Criteria

I am between 18 and 79 years old and need a first-time shoulder replacement.

Exclusion Criteria

Patients allergic to TXA

Patients with current tobacco use

I have had blood clots in my veins.

Treatment Details

Interventions

• Tranexamic Acid (Anti-fibrinolytic agent)

Trial Overview The study aims to assess the effects of oral tranexamic acid on patients' recovery shortly after they've had total shoulder arthroplasty compared to a placebo.

Participant Groups

Group I: oral tranexamic acid Experimental Treatment 1 Intervention

Group II: Oral Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials

1,677

Recruited

2,458,000+